Back to top
more

Tandem Diabetes Care (TNDM)

(Real Time Quote from BATS)

$45.82 USD

45.82
499,826

+1.52 (3.43%)

Updated Aug 27, 2024 03:14 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value C Growth B Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 29% (72 out of 251)

Industry: Medical - Instruments

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Tandem Diabetes Care, Inc. (TNDM) Reports Next Week: Wall Street Expects Earnings Growth

by Zacks Equity Research

Tandem Diabetes Care, Inc. (TNDM) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Here's Why You Should Hold on to Tandem Diabetes (TNDM) Stock

by Zacks Equity Research

Investors continue to be optimistic about Tandem Diabetes (TNDM) on robust pump sales and shipments.

Tandem Diabetes' (TNDM) Insulin Pump Approved by Health Canada

by Zacks Equity Research

Tandem Diabetes' (TNDM) t:slim X2 Insulin Pump with Control-IQ Advanced Hybrid Closed-Loop Technology cleared for use in Canada post the receipt of Health Canada approval.

Tandem Diabetes (TNDM) Q3 Earnings Miss, '20 Sales View Up

by Zacks Equity Research

Tandem Diabetes' (TNDM) strong domestic pump sales and pump shipments boosted the top line.

Zacks.com featured highlights include: The New York Times, Apple and Tandem Diabetes Care

by Zacks Equity Research

Zacks.com featured highlights include: The New York Times, Apple and Tandem Diabetes Care

Tirthankar Chakraborty headshot

3 Stocks to Watch Closely for Superb Earnings Acceleration

by Tirthankar Chakraborty

At present, the New York Times (NYT), Apple (AAPL) and Tandem Diabetes Care (TNDM) are some of the few companies boasting solid earnings acceleration.

Abbott's Libre 3 Receives CE Mark, Boosts CGM Prospects

by Zacks Equity Research

Abbott's (ABT) environment-friendly next-generation FreeStyle Libre 3 system aims to provide a better quality of life to diabetics in Europe at the same affordable price of previous systems.

    Insulet (PODD) Hits a New 52-Week High: What's Driving It?

    by Zacks Equity Research

    Insulet (PODD) is optimistic about maintaining growth momentum of its Omnipod system along with tapping the booming diabetes market.

    Debanjana Dey headshot

    3 Stocks to Buy From Strong MedTech Spaces Amid the Pandemic

    by Debanjana Dey

    Here are three stocks from three sub-sectors from MedTech that have held their ground despite the pandemic-led market mayhem.

    Debanjana Dey headshot

    4 Best Diabetes Device Stocks to Focus on Amid Coronavirus Crisis

    by Debanjana Dey

    Here are a few diabetes-centric MedTech stocks that investors can focus on to reap profits amid the pandemic-battered stock market situation.

    Medicare Coverage for Libre 2 Boosts Abbott's CGM Prospects

    by Zacks Equity Research

    Abbott's (ABT) FreeStyle Libre 2 iCGM is now available to Medicare-eligible diabetic patients via CMS' reimbursement expansion.

    Tandem Diabetes' Advanced Insulin Pump Study Results Favorable

    by Zacks Equity Research

    Per the DCLP5 study, Tandem Diabetes' (TNDM) insulin pump with Control-IQ technology suitable for use in children aged six to 13 years, which has been published in the NEJM.

    Medtronic Plans New Acquisition in AI-Driven Diabetes Care

    by Zacks Equity Research

    Medtronic's (MDT) acquisition of Companion Medical aims to expand service to diabetics using multiple daily injections for diabetes management.

    Urmimala Biswas headshot

    3 Medical Product Stocks Set to Beat This Earnings Season

    by Urmimala Biswas

    Here we discuss three medical product stocks that are due to report soon and are likely to beat estimates on earnings, riding on a host of factors.

    Tandem Diabetes (TNDM) Q2 Earnings & Revenues Top Estimates

    by Zacks Equity Research

    Tandem Diabetes' (TNDM) strong domestic pump sales and pump shipments boosted the top line.

    Sriparna Ghosal headshot

    3 Large-Cap MedTech Stocks to Buy on Northbound Market Trend

    by Sriparna Ghosal

    Backed by an upward trend of share prices and projections of robust earnings growth rates, there are a few MedTech stocks which are ideal for long-term bet.

    Abbott, Tandem Diabetes Seal Deal on Diabetes Management

    by Zacks Equity Research

    Abbott's (ABT) FreeStyle Libre CGM technology to be integrated with Tandem Diabetes' insulin pumps to enhance diabetes care.

    Tandem Diabetes' Sugarmate Buyout Boosts Digital Offerings

    by Zacks Equity Research

    Tandem Diabetes (TNDM) expands digital portfolio with the Sugarmate app buyout, paving the way for the company's expansion of diabetes-related products and services ecosystem.

    Tandem Diabetes Gets Expanded Indication for Insulin Pump

    by Zacks Equity Research

    Tandem Diabetes (TNDM) receives clearance for expanded indication for pediatric use of t:slim X2 insulin pump with Control-IQ, paving the way for simpler diabetes management in younger patient pool.

    Tandem Diabetes (TNDM) Looks Good: Stock Adds 6.5% in Session

    by Zacks Equity Research

    Tandem Diabetes (TNDM) saw a big move last session, as its shares jumped nearly 7% on the day, amid huge volumes.

    Sriparna Ghosal headshot

    3 Diabetes Management Stocks in the Spotlight Amid Coronavirus

    by Sriparna Ghosal

    Amid the widespread pandemic crisis, the diabetes management sector continues to thrive on account of multiple positive developments

    Tandem Diabetes Rides on Control-IQ Amid Coronavirus Crisis

    by Zacks Equity Research

    Strong domestic pump sales and international expansion boosts sales of Tandem Diabetes (TNDM).

    Here's Why You Should Hold on to Tandem Diabetes Stock for Now

    by Zacks Equity Research

    Investors continue to be optimistic about Tandem Diabetes (TNDM) on robust pump sales and international growth.

    Tandem Diabetes (TNDM) Q1 Loss Widens, Revenues Top Estimates

    by Zacks Equity Research

    Tandem Diabetes' (TNDM) strong domestic pump sales and the company's expansion in international markets boost the top line.

    Here's Why You Should Add Tandem Diabetes to Your Portfolio

    by Zacks Equity Research

    Investors continue to be optimistic about Tandem Diabetes (TNDM) on its strength in the diabetes business and receipt of regulatory approvals.